Urogen Drug Patent Portfolio
Urogen owns 2 orange book drugs protected by 5 US patents Given below is the list of Urogen's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US12268745 | Material and method for treating internal cavities | 20 Jan, 2031 | Active |
| US9040074 | Material and method for treating internal cavities | 20 Jan, 2031 | Active |
| US9950069 | Material and method for treating internal cavities | 20 Jan, 2031 | Active |
| US10039832 | Material And Method For Treating Internal Cavities | 20 Jan, 2031 | Active |
| US12440568 | Material And Method For Treating Internal Cavities | 20 Jan, 2031 | Active |
Latest Legal Activities on Urogen's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Urogen.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 8th Yr, Small Entity | 29 Jan, 2026 | US10039832 |
| Email Notification | 29 Oct, 2025 | US12440568 |
| Mail Miscellaneous Communication to Applicant | 29 Oct, 2025 | US12440568 |
| Miscellaneous Communication to Applicant - No Action Count | 28 Oct, 2025 | US12440568 |
| Recordation of Patent Grant Mailed | 21 Oct, 2025 | US12440568 |
| Patent eGrant Notification | 14 Oct, 2025 | US12440568 |
| Email Notification | 14 Oct, 2025 | US12440568 |
| Recordation of Patent eGrant | 14 Oct, 2025 | US12440568 |
| Mail Patent eGrant Notification | 14 Oct, 2025 | US12440568 |
| Patent Issue Date Used in PTA Calculation | 14 Oct, 2025 | US12440568 |
| Payment of Maintenance Fee, 8th Yr, Small Entity | 13 Oct, 2025 | US9950069 |
| Payment of Maintenance Fee, 8th Yr, Small Entity | 13 Oct, 2025 | US9950069 |
| Email Notification | 02 Oct, 2025 | US12440568 |
| Issue Notification Mailed | 01 Oct, 2025 | US12440568 |
| Application Is Considered Ready for Issue | 19 Sep, 2025 | US12440568 |
Urogen's Family Patents
Clinical Trials
Recent Clinical Trials by Urogen:
| Title | Lead Sponsor | Collaborators | Status | Phases |
|---|---|---|---|---|
 | ||||
| A Phase 3 Single-arm Study of UGN-104 for the Treatment of Low-grade Upper Tract Urothelial Cancer | UroGen Pharma Ltd. | NA |
RECRUITING
(Sep 1, 2026)
| PHASE3 |
| Enzalutamide With Lu PSMA-617 Versus Enzalutamide Alone in Men With Metastatic Castration-resistant Prostate Cancer | Australian and New Zealand Urogenital and Prostate Cancer Trials Group | NA |
ACTIVE NOT RECRUITING
(Jun 1, 2026)
| PHASE2 |
| A Phase 3 Single-Arm Study of UGN-102 for Treatment of Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer | UroGen Pharma Ltd. | NA |
ACTIVE NOT RECRUITING
(Apr 1, 2026)
| PHASE3 |
| Working Out M0 Bipolar Androgen Therapy | Australian and New Zealand Urogenital and Prostate Cancer Trials Group | NA |
RECRUITING
(Apr 1, 2026)
| PHASE2 |
Urogen Drug List
Given below is the complete list of Urogen's drugs and the patents protecting them.
1. Jelmyto
Jelmyto is protected by 3 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US12268745 | Material and method for treating internal cavities |
20 Jan, 2031
(4 years from now)
| Active |
| US9040074 | Material and method for treating internal cavities |
20 Jan, 2031
(4 years from now)
| Active |
| US9950069 | Material and method for treating internal cavities |
20 Jan, 2031
(4 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Jelmyto's drug page
2. Zusduri
Zusduri is protected by 4 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10039832 | Material And Method For Treating Internal Cavities |
20 Jan, 2031
(4 years from now)
| Active |
| US12440568 | Material And Method For Treating Internal Cavities |
20 Jan, 2031
(4 years from now)
| Active |
| US9040074 | Material and method for treating internal cavities |
20 Jan, 2031
(4 years from now)
| Active |
| US9950069 | Material and method for treating internal cavities |
20 Jan, 2031
(4 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Zusduri's drug page